Walleye Capital’s Arcturus Therapeutics ARCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$193K Buy
14,100
+12,600
+840% +$132K ﹤0.01% 4840
2026
Q2
$10.1K Buy
+1,500
New +$11.8K ﹤0.01% 4492
2026
Q1
– Sell
-4,000
Closed -$24.5K – 4356
2025
Q4
$24.5K Sell
4,000
-1,700
-30% -$18.4K ﹤0.01% 4224
2025
Q3
$105K Buy
5,700
+1,500
+36% +$24.1K ﹤0.01% 3690
2025
Q2
$54.6K Buy
+4,200
New +$49.7K ﹤0.01% 4011
2025
Q1
– Sell
-100
Closed -$1.7K – 4226
2024
Q4
$1.7K Buy
+100
New +$1.88K ﹤0.01% 4671
2024
Q3
– Sell
-14,700
Closed -$358K – 5245
2024
Q2
$358K Buy
14,700
+12,500
+568% +$379K ﹤0.01% 3819
2024
Q1
$74.3K Buy
+2,200
New +$78K ﹤0.01% 4534

Other funds holding ARCT

Walleye Capital's ARCT Position: Q3 2026 in Review

Walleye Capital increased its Arcturus Therapeutics (ARCT) stake by 435% in Q3 2026, buying an estimated $879K and bringing the position to 103,415 shares worth $1.42M. The position accounts for ﹤0.01% of the portfolio, ranked #3142.

Walleye Capital first reported a position in ARCT in Q1 2021 and has held it in 7 quarters since. 155 funds tracked by Wall St. Rank hold ARCT as of Q3 2026.

  • Walleye Capital held 103,415 shares of Arcturus Therapeutics worth $1.42M as of Q3 2026.
  • Walleye Capital bought 84,092 Arcturus Therapeutics shares in Q3 2026, an estimated $879K.
  • Arcturus Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #3142 holding.
  • Walleye Capital first reported a position in Arcturus Therapeutics in Q1 2021 and has held it in 7 quarters since.
  • 155 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.